Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 327

1.

Interferons and natalizumab for multiple sclerosis.

Clar C, Velasco Garrido M, Gericke C, Busse R.

GMS Health Technol Assess. 2008 Oct 1;4:Doc09.

2.

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.

Cochrane Database Syst Rev. 2013 Jun 6;(6):CD008933. doi: 10.1002/14651858.CD008933.pub2. Review.

PMID:
23744561
3.

Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].

Smith B, Carson S, Fu R, McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A.

Portland (OR): Oregon Health & Science University; 2010 Aug.

4.
5.

Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.

Chiao E, Meyer K.

Curr Med Res Opin. 2009 Jun;25(6):1445-54. doi: 10.1185/03007990902876040.

PMID:
19422279
6.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
7.
8.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
9.
10.

Natalizumab: new drug. Multiple sclerosis: risky market approval.

[No authors listed]

Prescrire Int. 2008 Feb;17(93):7-10.

PMID:
18354844
11.

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.

Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, Elias W, Obhof W, Viehöver A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdörfer C; QUASIMS Study Group.

J Neurol. 2007 Jan;254(1):67-77. Epub 2007 Feb 1.

PMID:
17273808
12.

Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Guo S, Bozkaya D, Ward A, O'Brien JA, Ishak K, Bennett R, Al-Sabbagh A, Meletiche DM.

Pharmacoeconomics. 2009;27(1):39-53. doi: 10.2165/00019053-200927010-00005.

PMID:
19178123
13.

Multiple sclerosis: interferon beta for some serious forms.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):252-7.

PMID:
18092425
14.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

PMID:
28440858
15.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

N Engl J Med. 2006 Mar 2;354(9):911-23.

16.

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

Brown MG, Murray TJ, Sketris IS, Fisk JD, LeBlanc JC, Schwartz CE, Skedgel C.

Int J Technol Assess Health Care. 2000 Summer;16(3):751-67.

PMID:
11028131
17.

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.

Galetta SL, Markowitz C, Lee AG.

Arch Intern Med. 2002 Oct 28;162(19):2161-9.

PMID:
12390057
18.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

19.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
20.

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.

Moses H Jr, Brandes DW.

Curr Med Res Opin. 2008 Sep;24(9):2679-90. doi: 10.1185/03007990802329959 . Epub 2008 Aug 8.

PMID:
18694542

Supplemental Content

Support Center